Thursday January 8, 2015 0 comments
LOUISVILLE - AntriaBio Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended-release therapies, announced it has successfully completed a series of in-vitro and multi-species animal pharmacology studies for AB101, a potential once-weekly basal insulin for patients with type 1 and type 2 diabetes.
AntriaBio said the studies assessed the receptor pharmacology, pharmacokinetics and pharmacodynamics of AB101 and support potential for a once-weekly basal insulin in patients.
The current standard of care in the $10 billion basal insulin market is a daily treatment, the company said.
"Despite the many advancements in therapy, there remain many challenges for patients with diabetes that may be mitigated by the availability of new, longer-lasting basal insulin therapy," said C. Ronald Kahn, chief academic officer and past president of Joslin Diabetes Center, the world's largest diabetes clinical care and research organization.
"If successful in human clinical studies and commercialized, AB101 could reduce the number of required injections and may even help transition insulin-averse patients and providers to earlier use of insulin."
AntriaBio said it is currently conducting additional studies, including ongoing toxicology studies that would support the filing of an Investigational New Drug application with the FDA for AB101 and the subsequent launch of a clinical study in type 1 diabetes patients this year.
"We are emboldened by the completion of these animal studies, which represent an exciting milestone toward advancing AB101 into clinical trials," said Brian Roberts, AntraiBio's VP of clinical development.